<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04159727</url>
  </required_header>
  <id_info>
    <org_study_id>18-22 Medibiote 1</org_study_id>
    <nct_id>NCT04159727</nct_id>
  </id_info>
  <brief_title>Gut Microbiota Dysbiosis and Translocation During IBD and Parkinson</brief_title>
  <acronym>Medibiote1</acronym>
  <official_title>Gut Microbiota Dysbiosis and Translocation Within Patients Suffering From Diseases Associated With Increased Intestinal Barrier Permeability : IBD and Parkinson</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hôpital Européen Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hôpital Européen Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Inflammatory bowel diseases (IBD) and Parkinson disease (PD) are complex and multifactorial
      pathologies. Gut microbiota seems to play an active role. Indeed the digestive microbiota of
      patients with IBD or PD exhibits different compositions compared with asymptomatic subjects.

      Bacterial translocation from gut to blood has been reported.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators designed a case-control study to investigate the digestive microbiota and
      bacterial translocation during IBD and PD. The investigators want to evaluate gut microbiota
      bacteria involved in dysbiosis and bacterial translocation during IBD and PD. The
      investigators want to identify bacterial populations that can serve as biomarkers for
      clinical practice.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 28, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>16S RNA sequencing in stool sample</measure>
    <time_frame>2 years</time_frame>
    <description>16S RNA sequencing to identify species constituting the microbiota in the stool</description>
  </primary_outcome>
  <primary_outcome>
    <measure>16S RNA sequencing in blood sample</measure>
    <time_frame>2 years</time_frame>
    <description>16S RNA sequencing to identify species constituting the microbiota in the blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stool quantification of key bacteria associated with intestinal barrier permeability.</measure>
    <time_frame>2 years</time_frame>
    <description>To determine stool rates of Faecalibacterium prausnitzii, Akkermansia muciniphila, Bacteroides fragilis, Clostridium difficile, Mycobacterium avium paratuberculosis and Escherischia coli by qPCR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood quantification of key bacteria associated with intestinal barrier permeability.</measure>
    <time_frame>2 years</time_frame>
    <description>To determine blood rates of Faecalibacterium prausnitzii, Akkermansia muciniphila, Bacteroides fragilis, Clostridium difficile, Mycobacterium avium paratuberculosis and Escherischia coli by qPCR</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Inflammatory Bowel Diseases</condition>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>IBD or PD patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 patients suffering from IBD 10 patients suffering from PD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Asymptomatic subjects</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>30 asymptomatic subjects matched to patients on age, sexe and BMI</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>stool and blood analysis</intervention_name>
    <description>High throughput sequencing and quantitative PCR</description>
    <arm_group_label>Asymptomatic subjects</arm_group_label>
    <arm_group_label>IBD or PD patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  PD patients : age &lt; or = 60 years

          -  asymptomatic subjects : no chronic disease

          -  asymptomatic subjects : no treatment

        Exclusion Criteria:

          -  severe anemia (Hb&lt;7g/L)

          -  people who don't read french

          -  pregnant women

          -  people treated by antibiotic, probiotic or prebiotic during the 2 month before
             inclusion

          -  people with any diagnosed or treated pathology
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe HALFON, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Européen Marseille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wahiba bidaut</last_name>
    <phone>(0)4 13 42 73 35</phone>
    <phone_ext>+33</phone_ext>
    <email>w.bidaut@hopital-europeen.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lucie Molet</last_name>
    <phone>(0)413428165</phone>
    <phone_ext>+33</phone_ext>
    <email>l.molet@alphabio.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>European Hospital</name>
      <address>
        <city>Marseille</city>
        <state>Bouches-du Rhone</state>
        <zip>13003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wahiba BIDAUT</last_name>
      <phone>(0)4 13 42 73 35</phone>
      <phone_ext>+33</phone_ext>
      <email>w.bidaut@hopital-europeen.fr</email>
    </contact>
    <contact_backup>
      <last_name>Lucie Molet</last_name>
      <phone>(0)413428165</phone>
      <phone_ext>+33</phone_ext>
      <email>l.molet@alphabio.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 16, 2019</study_first_submitted>
  <study_first_submitted_qc>November 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2019</study_first_posted>
  <last_update_submitted>November 8, 2019</last_update_submitted>
  <last_update_submitted_qc>November 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gut microbiota</keyword>
  <keyword>Bacterial translocation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Dysbiosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

